Search the Newsreel

FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer

Supplemental application aims to expand use to men with HRR gene-mutated metastatic castration-sensitive prostate cancer Filing supported by Phase 3 TALAPRO-3 data demonstrating greater than 50% improvement in radiographic progression-free survival, with consistent benefit across BRCA and non-BRCA HRR gene alterations NEW YORK, July …

Pfizer (PFE) Faces New Patent Lawsuits Over Covid 19 Vaccine Technology

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Arbutus Biopharma and Genevant Sciences have filed multiple patent infringement lawsuits against Pfizer and BioNTech over their mRNA-LNP COVID-19 vaccines. The new cases extend beyond …

Pfizer stock steadies as investors weigh post-COVID revenue mix and pipeline milestones

Pfizer is navigating a post-COVID transition, with revenue normalizing as sales of pandemic-related products decline significantly from their peak. The company is refocusing on its core pharmaceutical portfolio, including oncology, vaccines, and internal medicine, and emphasizes rebuilding sustainable revenue growth from these areas and …

Bluesight and Pfizer Partner to Provide Source-Tagged RFID Medications to Hospital Pharmacies

BluesightCoveer Image ALEXANDRIA, Va., July 22, 2026 (GLOBE NEWSWIRE) -- Pfizer's SmartDose medications arrive pre-tagged and pre-associated for use with KitCheck, reducing manual tagging labor as part of RFID inventory management workflows Bluesight, the leader in hospital intelligence solutions, today announced a partnership with …

Pfizer (PFE) Stock Seems Fairly Priced As Oncology Approvals Build

Pfizer's stock, though down over five years, appears fairly priced based on current valuation checks and a P/E ratio of 18.9x, which aligns closely with Simply Wall St's fair P/E of 19.7x. The company's recent oncology and weight-loss drug approvals are balanced by patent …

What to Watch in Pfizer's Non-Oncology Portfolio This Earnings Season

Pfizer PFE will announce its second-quarter 2026 earnings on Aug. 4, and investors will be watching the performance of its oncology business closely, as the segment generates nearly 27% of the company's total revenues. Its key cancer medicines include Ibrance, Xtandi, Lorbrena, Braftovi/Mektovi and …

Net income of Pfizer Inc. – BCS:PFECL1

The article provides a title related to the net income of Pfizer Inc. with the stock symbol BCS:PFECL1. It indicates that the market for this particular stock on the Santiago Stock Exchange was closed with no trades. The content is mostly boilerplate from TradingView, …

Pfizer stock trades steady as recent earnings and pipeline updates frame valuation

Pfizer's stock performance reflects a transition from peak Covid-19 revenues to a diversified portfolio. The company's revenue normalized to around $58 billion after exceeding $100 billion during the pandemic, driven by declining Covid-related product sales, while its non-Covid businesses show more stable growth. Valuation …

Pfizer (PFE) Falls More Steeply Than Broader Market: What Investors Need to Know

Pfizer (PFE) shares dropped 1.2% in the last trading session, underperforming the broader S&P 500 and Dow. The company is set to release its Q3 earnings on August 4, 2026, with analysts expecting a decline in both EPS and revenue compared to the prior …

Pfizer Suspends Popular Menopause Cream in India

Pfizer has temporarily suspended the distribution of its Premarin vaginal cream in India due to unspecified supply chain difficulties, significantly reducing estrogen therapy options for women. This move impacts over 620,000 units sold annually and leaves few alternatives for genitourinary syndrome of menopause in …

Pfizer (PFE) Faces New International Patent Lawsuits Over Covid 19 Vaccine

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Arbutus Biopharma and Genevant Sciences have filed multiple patent infringement lawsuits against Pfizer and BioNTech over their mRNA-LNP COVID-19 vaccines. The new cases extend beyond …

Is Trending Stock Pfizer Inc. (PFE) a Buy Now?

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this drugmaker have returned -0.6% over the past …

Axios C-Suite: Pfizer CEO on biotech's China warning

Pfizer CEO Albert Bourla addresses the growing influence of China in the biotech industry, noting its rapid rise as a scientific superpower due to lower costs and faster development. He advises other CEOs to confront both the threats and opportunities China presents, emphasizing a …

Pfizer site developer’s complex conversion technique draws attention after collapse scare

Nathan Berman's complex conversion technique at a former Pfizer site has come under scrutiny after a collapse scare. Falling debris from a 37-story Midtown Manhattan building undergoing office-to-residential conversion led to building evacuations and street closures. The incident draws attention to the challenging engineering …

Pfizer Inc. (PFE) Stock Analysis: Evaluating a 14.92% Potential Upside Amidst Strong Dividend Yield

This article analyzes Pfizer Inc. (PFE), highlighting its potential 14.92% upside and strong 6.87% dividend yield. While performance metrics and strategic collaborations suggest growth, the high 131.30% payout ratio raises questions about dividend sustainability. Analyst sentiment is mixed, indicating cautious optimism, while technical indicators …

Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market?

Pfizer is actively developing several weight management drugs and recently acquired Metsera, significantly boosting its pipeline in this growing market. While Pfizer has promising candidates, particularly MET-097i with potential for monthly dosing, it faces strong competition from market leaders like Eli Lilly and Novo …

Lobbying Update: $60,000 of PFIZER lobbying was just disclosed

A recent Lobbying Disclosure Act filing revealed that Pfizer (PFE) disclosed $60,000 in lobbying expenditures for Q2 2026. The lobbying efforts focused on issues including drug development and pricing, vaccine safety and access, the 340B program, and pharmacy benefit managers. The article also provides …

Pfizer (NYSE:PFE) shares rise 3.6% on dividend strength as analyst forecasts remain unchanged

Pfizer (NYSE:PFE) shares rose 3.6% last week, outperforming the S&P 500, primarily due to the appeal of its 6.9% dividend yield rather than an increase in earnings forecasts. Analyst expectations for 2026 earnings actually saw a slight decrease. The company also saw a new …

Enanta v. Pfizer is Not About a Typo: It is About Possession of the Invention

The article argues that the Enanta v. Pfizer case is not merely about a typographical error in a patent application, but rather about whether the inventors possessed the invention prior to Pfizer's public disclosure of nirmatrelvir. It claims the Federal Circuit applied the wrong …

The Pfizer-BioNTech COVID-19 Vaccine. Updated formulation keeps Comirnaty relevant

The Pfizer-BioNTech COVID-19 Vaccine (Comirnaty) continues to be a key product for Pfizer, with updated formulations targeting current SARS-CoV-2 variants. The article details its development, regulatory approvals for various age groups, manufacturing and distribution challenges including cold chain requirements, and its safety profile based …

Pfizer Stock Leads 3 AI Healthcare Names Worth Further Research

This article identifies three AI healthcare stocks—Pfizer (PFE), Tempus AI (TEM), and Medtronic (MDT)—as compelling for further research, given the growing importance of AI in diagnostics, treatment, and efficiency within the healthcare sector. It highlights their individual strengths, such as Pfizer's broad portfolio and …

Pfizer (PFE) Could Be 16% Undervalued On New FDA Approval In Bladder Cancer

Pfizer (PFE) recently received FDA approval for PADCEV plus Keytruda for muscle-invasive bladder cancer, which could suggest a 16% undervaluation based on a fair value of $29.19 per share. Despite past share price pressure, the new oncology approval and strong late-stage pipeline in oncology …

ETFs Investing in Pfizer Inc. Stocks

This article lists numerous Exchange Traded Funds (ETFs) that hold Pfizer Inc. (PFE) stocks. It provides a detailed table including each ETF's market value, weight of PFE in the fund, issuer, management style, focus, expense ratio, AUM, price, change, relative volume, and 3-year NAV …

EXCLUSIVE: Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges

Pfizer has temporarily suspended sales of Premarin vaginal cream in India due to supply challenges, significantly impacting the estrogen therapy options for millions of women experiencing menopause-related symptoms in the country. This suspension affects over half of the market for this type of medication …

Pfizer Stock Below 50-Day and 200-Day SMA: Buy the Dip or Exit Now?

Pfizer's stock is trading below its 50-day and 200-day simple moving averages, indicating investor caution due to declining COVID-related revenues and upcoming patent expirations. Despite these challenges and a dull 2026 financial outlook, the company is rebuilding its pipeline in oncology and obesity through …

Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders

Arbutus Biopharma, along with its licensee Genevant, has filed three international lawsuits against Pfizer and BioNTech for patent infringement related to their LNP technology used in COVID-19 vaccines. The company also announced it received approximately $178 million from Moderna as part of a settlement …

Is Earlier‑Stage PADCEV‑Keytruda Approval Reshaping The Investment Case For Pfizer (PFE)?

Pfizer and Astellas recently secured FDA approval for PADCEV plus Keytruda for earlier-stage muscle-invasive bladder cancer, which broadens PADCEV’s application and reinforces Pfizer's oncology focus. While this strengthens Pfizer’s near-term cancer pipeline, the article notes that it doesn't fully mitigate the larger concerns of …

Sanofi sues Pfizer, Moderna over COVID shot technology

Sanofi has filed lawsuits against Pfizer and Moderna, alleging that their COVID-19 vaccines infringe on multiple patents held by the French pharmaceutical company. The lawsuits claim that the mRNA innovations used in Pfizer and Moderna's blockbuster vaccines violate Sanofi's patent rights, specifically those covering …

Sanofi Sues Moderna, Pfizer for Vaccine-Tech Patent Royalties

Sanofi has filed federal lawsuits against Moderna Inc. and Pfizer Inc., seeking patent royalties for their COVID-19 and RSV vaccines. Sanofi alleges that these vaccines infringe upon as many as 10 of its mRNA delivery patents. The lawsuits were filed in the US District …

Pfizer (PFE) Announces FDA Approval of PADCEV plus Keytruda in MIBC

Pfizer and Astellas Pharma announced FDA approval of PADCEV plus Keytruda as a neoadjuvant and adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC), marking the first platinum-free regimen approved for MIBC regardless of cisplatin eligibility. This approval expands on a previous FDA …

Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity?

Pfizer and Gilead Sciences are presenting a contrarian investment opportunity as both stocks have experienced "death crosses" but trade below Wall Street consensus targets. Pfizer appears to be the more compelling contrarian setup due to its attractive 8x forward P/E and 7% dividend yield, …

Pfizer’s EPS Has Fallen 65% From Its Peak, Here’s Why That Might Be the Point

Pfizer Inc. (PFE) Stock: FDA Clears IBRANCE for HER2+ Breast Cancer

Pfizer-Aktie fällt nach Bestätigung der Prognose für das Geschäftsjahr 2026

Pfizer (PFE) Stock: Pfizer’s $26 Share Price and 6.6% Dividend Yield Face Drug Pricing and Patent Pressure

Pfizer Stock at $25: A $29 Wall Street Mean Target Backed by Two Legal Wins and 22% Portfolio Growth